Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rodin Therapeutics Inc.

Epigenetic agents for treating cognitive disorders

This article was originally published in Start Up

Executive Summary

Epigenetics continues to be a hot experimental field, but few drugs for modifying gene transcription to control cell-cycle progression have been tried out for central nervous system disorders despite scientific evidence linking aberrant epigenetic processes to several neurodegenerative conditions. Rodin Therapeutics Inc. is stepping in by bringing together international expertise in structural biology with CNS drug development leadership to discover and develop epigenetic agents for Alzheimer’s disease and other CNS disorders.

You may also be interested in...

Rodin Thinks Selective HDAC2 Inhibition Will Prove Better Therapeutic Approach To Alzheimer’s

Epigenetics-focused company believes a selective HDAC2 inhibitor could provide a safe way to treat signs and symptoms of Alzheimer’s. Having raised $12.9 million in Series A funding, Rodin hopes to move from lead optimization to clinical development over the next 18 to 24 months.

Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?

The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.

The Conundrum Of Alzheimer’s Disease R&D

Alzheimer’s disease science is in disarray and the risk associated with developing disease-modifying agents has driven many players from the field. But venturesome biotechs are finding backers to support efforts to look for a way forward: we profile Alzheon Inc., Neurotrack Inc., Rodin Therapeutics Inc., and Tetra Discovery Partners LLC.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts